The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Primary Membranous Nephropathy
Open accessAbstract
Membranous nephropathy (MN) is a unique glomerular lesion that is the most common cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are renal limited (primary MN, PMN) and 20% are associated with other systemic diseases or exposures (secondary MN). This review focuses only on PMN. Most cases of PMN have circulating IgG4 autoantibody to the podocyte membrane antigen PLA2R (70%), biopsy evidence PLA2R staining indicating recent immunologic disease activity despite negative serum antibody levels (15%), or serum anti-THSD7A (3%–5%). The remaining 10% without demonstrable anti-PLA2R/THSd7A antibody or antigen likely have PMN probably secondary to a different, still unidentified, anti-podocyte antibody. Considerable clinical and experimental data now suggests these antibodies are pathogenic. Clinically, 80% of patients with PMN present with nephrotic syndrome and 20% with non-nephrotic proteinuria. Untreated, about one third undergo spontaneous remission, especially those with absent or low anti-PLA2R levels, one-third progress to ESRD over 10 years, and the remainder develop nonprogressive CKD. Proteinuria can persist for months after circulating anti-PLA2R/THSD7A antibody is no longer detectable (immunologic remission). All patients with PMN should be treated with supportive care from the time of diagnosis to minimize protein excretion. Patients with elevated anti-PLA2R/THSD7A levels and proteinuria >3.5 g/d at diagnosis, and those who fail to reduce proteinuria to <3.5 g after 6 months of supportive care or have complications of nephrotic syndrome, should be considered for immunosuppressive therapy. Accepted regimens include steroids/cyclophosphamide, calcineurin inhibitors, and B cell depletion. With proper management, only 10% or less will develop ESRD over the subsequent 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y. H., Franz, S., Delfgaauw, J., Chang, J.-M., Choi, H. Y., Campbell, K. N., Kim, K., et al. (2008) · Nature Medicine · doi:10.1038/nm.1857 · Cited by 991
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Tomas, N. M., Beck, L. H., Meyer-Schwesinger, C., Seitz-Polski, B., Ma, H., Zahner, G., Dolla, G., Hoxha, E., Helmchen, U., Dabert-Gay, A.-S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409354 · Cited by 945
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 865
Antenatal Membranous Glomerulonephritis Due to Anti–Neutral Endopeptidase Antibodies
Debiec, H., Guigonis, V., Mougenot, B., Decobert, F., Haymann, J.-P., Bensman, A., Deschênes, G., & Ronco, P. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012895 · Cited by 528
Risk HLA-DQA1 and PLA 2 R1 Alleles in Idiopathic Membranous Nephropathy
Stanescu, H. C., Arcos-Burgos, M., Medlar, A., Bockenhauer, D., Kottgen, A., Dragomirescu, L., Voinescu, C., Patel, N., Pearce, K., Hubank, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009742 · Cited by 523
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China
Xu, X., Wang, G., Chen, N., Lu, T., Nie, S., Xu, G., Zhang, P., Luo, Y., Wang, Y., Wang, X., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010093 · Cited by 476
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040449 · Cited by 439
Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070640 · Cited by 376
Cited by
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy
Sethi, S., Debiec, H., Madden, B., Charlesworth, M. C., Morelle, J., Gross, L., Ravindran, A., Buob, D., Jadoul, M., Fervenza, F. C., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.014 · Cited by 360
Immunology of the ageing kidney
Sato, Y., & Yanagita, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0185-9 · Cited by 126
Metadata
- Authors
- Couser, W. G.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-05-26
- Volume
- 12
- Issue
- 6
- Pages
- 983-997
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2617482626
- Cited by
- 690
- References
- 39
- FWCI
- 30.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary Membranous Nephropathy. https://app.cochat.ai/papers/10.2215/cjn.11761116
- The paper
- Couser, W. G. (2017). Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.11761116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.